Request Investor Info

Defence Therapeutics: Developing Next Generation Biopharmaceutical Innovations

October 26, 2022

Stocks to Invest in: Healthcare

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cell.

Defence Therapeutics is a Canadian Biotech developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectiousdiseases (ID) indications

‍

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

Latest Articles

Centurion CEO Romundt Sees Generational Opportunity in Real Estate Finance

TD Q U.S. Small-Mid-Cap Equity ETF Offers an Investment Opportunity Not Seen in a Long Time ETFs

Mission Critical: How XPhyto Therapeutics Could Revolutionize PCR Testing Cannabis

Algernon Pharmaceuticals: Investigating a Novel Therapy for Stroke Patients Using the Psychedelic Drug N,N-Dimethyltryptamine (DMT)Healthcare

Hot Companies

Aston Bay Holdings

KITS Eyecare Ltd.

You might also like

Lexaria Bioscience: Transforming GLP-1 Drug Delivery for a Growing Market

Lexaria Bioscience is advancing GLP-1 drug delivery, aiming to improve effectiveness and reduce side effects for this fast-growing market.

Sernova: Advancing the Future of Diabetes Treatment

Sernova's clinical trials for type 1 diabetes have led to multiple patients achieving insulin independence and stable long-term blood sugar levels.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!